TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00964912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 3 mg, single dose, one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.5 mg, single dose, one dose
Study: NCT03136822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dressing
Description: Standard dressing is applied for treatment of diabetic foot ulcers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMALIX
Description: DERMALIX, a class III Medical Device will be applied in addition to standard dressing
Study: NCT01479010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously daily
Description: Anakinra 100 mg subcutaneously daily
Study: NCT03387566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1M
Description: HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1M
Description: HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
Study: NCT01660659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomass Briquettes and Rocket stove
Description: Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
Study: NCT03907553

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted genome sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted genome sequencing
Study: NCT01009125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $2 cash
Description: $2 cash incentive will be included in the mailed survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $5 cash
Description: $5 cash incentive will be included in the mailed survey
Study: NCT01508858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel / ethinylestradiol
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levonorgestrel / ethinylestradiol
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
Study: NCT02739204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
Study: NCT00491998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V1512
Description: 6 doses of IMP at 2-hourly intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V1512
Description: 3-hourly dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: V1512 and Entacapone
Description: 4 doses of IMP and Entacapone at 3-hourly intervals
Study: NCT01339429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simplified negative pressure wound therapy device (Wound Pump device)
Description: A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
Study: NCT04490538

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Conventional transthoracic echocardiographic examination at the intensive care unit.
Study: NCT02088255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static surface
Description: During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic surface
Description: During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
Study: NCT04339127

Intervention type: OTHER
Intervention: Description and analysis
Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
Study: NCT02141243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual Frenotomy
Description: For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual Frenotomy
Description: For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labial Frenotomy
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labial Frenotomy
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
Study: NCT03462264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoliogold App
Description: The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Formatted Diary
Description: The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
Study: NCT01899300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal Stent (WallFlex™ Esophageal RX)
Study: NCT03526237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24 week community based DPP Group Lifestyle Balance Program
Description: a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control community based DPP Group Lifestyle Balance Program
Description: Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
Study: NCT04502264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand of Hope
Description: A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
Study: NCT04502264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: A safe agent representing the gold standard treatment for focal spasticity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A injection
Description: A safe agent representing the gold standard treatment for focal spasticity.
Study: NCT02202213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Study: NCT00918320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide/Hycamtin (Topotecan)
Description: Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes
Study: NCT04018820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
Study: NCT00003675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: 1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
Study: NCT03387566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1M
Description: HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
Study: NCT01346787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
Description: Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
Study: NCT02849483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
Study: NCT04015284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block + Posterior Cord Block
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
Study: NCT03314402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Dihydrochloride Monohydrate
Description: Active Substance
Study: NCT04618640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV combination vaccine
Description: Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
Study: NCT04015284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Brachial Plexus Block
Description: The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
Study: NCT03965884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: Physical therapy and rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: Physical therapy and rehabilitation
Study: NCT03811925

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty and drug coated balloon of the superficial femoral artery (SFA)
Description: In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
Study: NCT03314402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT04880525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
Study: NCT05600491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
Study: NCT02707874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI 0.2% ropivacaine
Description: Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIB 0.2% ropivacaine
Description: Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
Study: NCT03811925

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty and stenting of the superficial femoral artery (SFA)
Description: In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
Study: NCT00052091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Supportive Therapy
Description: A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
Study: NCT02455661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Band (TM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioSeal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StarClose
Study: NCT01380535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP Methoxsalen
Description: Methoxsalen delivered by ECP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Study: NCT02013206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Erlotinib tablets taken orally once daily in the morning.
Study: NCT00572585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04140851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber intervention
Description: Dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal diet
Description: Normal diet
Study: NCT04744142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone supplementation
Description: Subjects receive either placebo or ketone ester supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone supplementation
Description: Subjects receive either placebo or ketone ester supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Description: Subjects receive either normal or increased protein intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Description: Subjects receive either normal or increased protein intake
Study: NCT01531439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Naloxone infusion 0.5 mcg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone infusion 2.5 mcg/kg/hr
Study: NCT02583958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 3103166
Description: URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Extra
Description: Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
Study: NCT03196219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: C16G2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: C16G2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: C16G2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Varnish Placebo
Study: NCT01901198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
Description: Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon 180 mcg single dose S.C.
Description: Pegasys 180 mcg S.C. single dose on Day 0
Study: NCT04614753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dealcoholized Muscadine Wine
Description: 300 ml of Dealcoholized Muscadine Wine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dealcoholized Muscadine Wine
Description: 300 ml of Dealcoholized Muscadine Wine
Study: NCT01059799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study: NCT04614753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Beverage
Description: 300ml of Sugar Water and Acid Content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Beverage
Description: 300ml of Sugar Water and Acid Content
Study: NCT01059799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study: NCT01447095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin 1 ng/kg/min
Description: Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin 2 ng/kg/min
Description: Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous i.v. infusion with placebo day 5-10 after SAH
Study: NCT00821977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04128267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPC-1000
Description: Delivers pressure to thumbnail for five seconds at a time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Scan of brain using Magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Administration of questionnaires via computer
Study: NCT02726646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.